Translate this page into:
Bone Scan: Indications Revisited
Address for correspondence: Dr. Madhur Kumar Srivastava, Department of Nuclear Medicine, NIMS, Hyderabad - 500 082, Telangana, India. E-mail: drmadhur77@yahoo.co.in
-
Received: ,
Accepted: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Skeletal scintigraphy is one of the most widely performed investigations in any nuclear medicine department. However, there has been a paradigm shift in the indications for which bone scan was performed in the past 3 decades, mainly due to advancement in other imaging modalities, better disease understanding, and the development of newer disease-specific guidelines. The metastatic indications for bone scans accounted for 60.3% of cases in 1998 which reduced to 15.5% in 2021 and nonmetastatic indications rose from 39.7% in 1998 to 84.5% in 2021. Fewer bone scans are being performed for the metastatic survey, and more scans are being performed for nononcological orthopedic and rheumatological indications. This article captures the journey of skeletal scintigraphy in the past three decades.
Keywords
Bone scan
nonmetastatic indications
skeletal scintigraphy
Introduction
Skeletal scintigraphy or bone scan is a well-established imaging technique in the nuclear medicine department. It is performed using technetium 99m-methylene diphosphonate (Tc99m MDP) on a gamma camera or single-photon emission computed tomography single-photon emission computed tomography (SPECT)- or fluorine-18 sodium fluoride (F-18 NaF) on a positron emission tomography-CT (PET-CT) scanner. Since the discovery of Tc-99m MDP by Subramanian and McAfee in 1971[1] and its superiority over other bone-seeking radiopharmaceuticals,[2] it is one of the most used radiotracers for bone imaging and bone scan, per se, remains one of the most commonly performed investigations in any nuclear medicine department. The changes in the indications of bone scans over the past three decades and the various causes behind them are discussed.
Materials and Methods
This study was conducted in a nuclear medicine center situated in a tertiary care university hospital which is operational since 1987. It is a retrospective analysis of the various indication with which the referring clinician had sent the patients for skeletal imaging. The data were collected from the departmental records.
Randomly, 1 year was selected from different decades, and bone scan indications were evaluated. The years selected were 1998, 2012, and 2021. All the bone scans done in that 1 year from January 1 to December 31 were evaluated for the referring physician indications. For analysis purposes, the result of the bone scan was not taken into account. The diagnosis, made by the referring physician, and clinically relevant history were considered for determining the indication for the bone scan. The indications were broadly divided into metastatic and nonmetastatic indications. The nonmetastatic indications were further divided into the infection-related, metabolic bone scan, i.e., renal osteodystrophy, hyperparathyroidism, osteoporosis (including insufficiency fracture), occult fracture evaluation, arthritis evaluation, pain related i.e., nonspecific body pain, low backache, limb pain, etc., prosthesis-related, and miscellaneous indications such as Paget's disease, fibrous dysplasia, and vascularity. In case of overlap of indication, like prosthetic evaluation presenting with pain, whose final diagnosis was an infection-related complication, the indication was considered under prosthesis related. Similarly, when a known case of Paget's disease presented with pain and bone scan was done to look for multiple sites of involvement, the indication was considered under the miscellaneous category.
The F-18 NaF bone scans were not included in the study for analysis because they were not performed in 1998 and 2012 at our institute.
Results
The number of Tc99m-MDP bone scans performed in 1998, 2012, and 2021 was analyzed in this study. In 1998, a total of 1003 bone scans were performed, of which 605 (60.3%) were for metastatic or malignancy workup while 398 (39.7%) were for the nonmetastatic cause. Similarly, in 2012, 978 bone scans were performed, of which 545 (55.7%) were for metastatic/malignancy workup and 433 (44.3%) were for the nonmetastatic cause. In 2021, a total of 530 bone scans were performed, out of which 82 (15.5%) were for metastatic or malignancy workups, and the rest 448 patients (84.5%) had a bone scan done for nonmetastatic work-up [Figure 1]. The number in 2021 was less due to the COVID-19 pandemic.

In the nonmetastatic category [Figure 2], the most common indication in 1998 was pain-related, accounting for 45.5% with 181 patients out of 398 getting a bone scan done for pain. This was reduced to 11.5% in 2012 (50 patients out of 433) and further reduced to 10.5% in 2021 (47 patients out of 448) [Figure 3], due to advancements in other imaging modalities such as musculoskeletal (MSK) magnetic resonance imaging (MRI), and Ultrasonography (USG). The second largest indication in the nonmetastatic category was arthritis-related indications, accounting for 33% in 1998 (131 patients out of 398 patients) which remained fairly stable in 2012 at 30% (130 patients out of 433) and 35.3% in 2021 (158 patients out of 448) [Figure 4]. Similarly, indications for fracture evaluation were 7.5% in 1998 (30 patients in 398) which increased to 11.4% in 2012 (49 patients in 433) and 4.2% in 2021 (19 patients in 448). The major change was seen in infection-related indications, which increased from 4% in 1998 (16 patients out of 398) to 24.9% in 2012 (108 patients out of 433) and 26.3% in 2021 (118 patients out of 448) [Figure 5]. Similarly, prosthesis-related indications increased from 2% (8 patients out of 398) in 1998-2.5% in 2012 (11 patients out of 433) and 9.6% in 2021 (43 patients out of 448) [Figure 6]. The indications for metabolic bone scan and insufficiency fracture were 3% in 1998, increased to 16.2% in 2012, and in 2021, it accounted for 8.5% of all nonmetastatic indications [Figure 7]. The miscellaneous causes, which included all other indications, not present in other categories, as described above, are fairly stable at 5% in 1998, 3.5% in 2012, and 5.6% in 2021 [Figures 8 and 9].








Discussion
Tc99m MDP skeletal scintigraphy or bone scan, one of the commonly performed investigations in the nuclear medicine department, has shown a paradigm shift in the indications for the scan due to various reasons, such as the development of other imaging modalities – PET-CT, MSK-MRI, and USG. The literature search yielded an article by Ryan and Fogelman[3] who also echoed a similar change in 1995 in the United Kingdom with a reduction in metastatic indication and an increase in benign orthopedic conditions. In the Indian scenario, this shift from metastatic to nonmetastatic indications was much later, primarily due to the delay in the launch of PET-CT. The first only PET scanner was established in India at Radiation Medicine Centre, Mumbai, in October 2002, which was followed by the first PET-CT scanner at Tata Memorial Hospital, Mumbai, in December 2004.[45] Since then, the number of PET-CT scanners has grown tremendously with more than 222 PET-CT centers in 2018.[4] As the PET-CT study provided much comprehensive information in terms of tumor size (T), nodal status (N), and other metastatic sites (M), it scores over bone scans which tells only about skeletal involvement in malignancy. This has been the biggest cause for the reduction in metastatic indications. Another major reason is the induction of PET-CT imaging in various cancer management guidelines such as NCCN Guidelines. Now, PET-CT imaging is part of Bone Cancer NCCN Guidelines and NCCN Evidence blocks ver. 1.2023 in bone lesions in age ≥40 years.[6] PET-CT imaging has been included in chordoma, Ewing sarcoma, and osteogenic sarcoma management.[6] The most common cause of skeletal metastases in males is prostate cancer and in females, breast cancer.[7] With the advent of theranostics and prostate-specific membrane antigen (PSMA)-based therapy with lutetium-177 and actinium-225 for prostatic carcinoma,[8] more and more patients are undergoing gallium-68 PSMA or fluorine-18 PSMA PET-CT scan, instead of conventional bone scan wherein if tracer localization is seen on these PET-CT studies, patients have an opportunity to be treated by the PSMA-based therapies.
In nonmetastatic indication, pain-related indication for skeletal scintigraphy was maximum, which showed a significant reduction in subsequent decades, mainly due to advancement in other imaging modalities such as multidetector CT, advancement in MSK-MRI techniques, HRUSG, and better workstations.[9] There has been a substantial increase in bone scan indications related to prosthesis evaluation. This has been due to manifold in numbers of prosthetic surgeries being performed, due to increased life expectancy, an aging population leading to more painful joints,[10] and better, much wider, availability of resources. In the Indian scenario, the number of total knee replacement (TKR) surgeries in 2006 was 1019, which increased to around 27,000 in 2019 with similar trends in total hip replacement surgeries.[10] Due to this increase in the absolute number of TKR surgeries, the number of revision TKR surgeries also showed an absolute increase in number with infection being the most common cause,[11] and a 3-phase bone scan is the preferred nuclear medicine study in patients of total joint arthroplasty presenting with pain,[12] leading to the total increase in many prosthesis-related cases presenting for the bone scan.
There is also an increase in other infection-related indications, such as vertebral spondylodiscitis and osteomyelitis, which accounted for 26.3% of all nonmetastatic indications in 2021, the reasons could be attributed to an aging population, increased surgical procedures in the older population, increased incidence of comorbidities such as diabetes mellitus leading to immunocompromised state, and improved detection rate due to better availability of imaging services.[13] There was an increase in the number of patients visiting the nuclear medicine department with a clinical diagnosis of metabolic bone disease, as described previously, from 3% to 16.2%, mainly attributed to a better understanding of these disease pathophysiology but then showed a decline to almost half to 8.5% in 2021. This decline is due to improved biochemical analysis and better imaging modalities, especially MRI, but most importantly development of multiple disease-related guidelines such as AACE/ACE 2016 – postmenopausal osteoporosis guidelines,[14] KDIGO 2017 guidelines for chronic kidney disease-mineral and bone disorder,[15] and many others. The indications for arthritis remained almost similar in the past 3 decades between 30% and 35%. The miscellaneous indications which included conditions such as osteoid osteoma, fibrous dysplasia, Paget's disease, and a few rarer conditions such as melorheostosis also remained the same at ~ 5%.
In conclusion, there has been a significant shift in the skeletal scintigraphy indications from metastatic to nonmetastatic ones due to advancements in technologies and a better understanding of the disease process. At present, the common orthopedic and rheumatological indications are arthritis evaluation, prosthesis-related complications, evaluation of radiologically occult fractures/infections, and metabolic bone diseases.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Technetium-99m-methylene diphosphonate – A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med. 1975;16:744-55.
- [Google Scholar]
- 2023 Bone Cancer. Available from: https://www.nccn.org/guidelines/guidelines-detail?category =1&id=1418
- Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study. PLoS One. 2020;15:e0234927.
- [Google Scholar]
- Evolution of the digital revolution: A radiologist perspective. J Digit Imaging. 2003;16:324-30.
- [Google Scholar]
- Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am. 2015;97:1386-97.
- [Google Scholar]
- India joining the World of Hip and Knee registries: Present status-a leap forward. Indian J Orthop. 2021;55:46-55.
- [Google Scholar]
- Nuclear medicine scans in total joint replacement. J Bone Joint Surg Am. 2021;103:359-72.
- [Google Scholar]
- Spondylodiscitis: Diagnosis and treatment options. Dtsch Arztebl Int. 2017;114:875-82.
- [Google Scholar]
- American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016 – Executive summary. Endocr Pract. 2016;22:1111-8.
- [Google Scholar]
- Kidney Int Suppl. 2011;2017(7):1-59.
